We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Live Oak Acquisition Corp. (“LOAK” or the “Company”) (NYSE: LOAK) in connection with the Company’s proposed merger with privately-held biotech company Danimer Scientific (“Danimer”).  Under the terms of the merger agreement, LOAK will acquire Danimer through a reverse merger that will result in Danimer becoming a publicly-listed company on the New York Stock Exchange under a new ticker symbol.  The transaction implies an equity value of $890 million for Danimer.

‍WeissLaw is investigating whether LOAK’s board acted in the best interest of LOAK’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Danimer, and whether all information regarding the valuation of the transaction will be fully and fairly disclosed to LOAK public shareholders.\n\nWeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com